Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study

Abstract

Objectives To develop and validate updated QRISK3 prediction algorithms to estimate the 10 year risk of cardiovascular disease in women and men accounting for potential new risk factors. Design Prospective open cohort study. Setting General practices in England providing data for the QResearch database. Participants 1309 QResearch general practices in England: 981 practices were used to develop the scores and a separate set of 328 practices were used to validate the scores. 7.89 million patients aged 25-84 years were in the derivation cohort and 2.67 million patients in the validation cohort. Patients were free of cardiovascular disease and not prescribed statins at baseline. Methods Cox proportional hazards models in the derivation cohort to derive separate risk equations in men and women for evaluation at 10 years. Risk factors considered included those already in QRISK2 (age, ethnicity, deprivation, systolic blood pressure, body mass index, total cholesterol: high density lipoprotein cholesterol ratio, smoking, family history of coronary heart disease in a first degree relative aged less than 60 years, type 1 diabetes, type 2 diabetes, treated hypertension, rheumatoid arthritis, atrial fibrillation, chronic kidney disease (stage 4 or 5)) and new risk factors (chronic kidney disease (stage 3, 4, or 5), a measure of systolic blood pressure variability (standard deviation of repeated measures), migraine, corticosteroids, systemic lupus erythematosus (SLE), atypical antipsychotics, severe mental illness, and HIV/AIDs). We also considered erectile dysfunction diagnosis or treatment in men. Measures of calibration and discrimination were determined in the validation cohort for men and women separately and for individual subgroups by age group, ethnicity, and baseline disease status. Main outcome measures Incident cardiovascular disease recorded on any of the following three linked data sources: general practice, mortality, or hospital admission records. Results 363 565 incident cases of cardiovascular disease were identified in the derivation cohort during follow-up arising from 50.8 million person years of observation. All new risk factors considered met the model inclusion criteria except for HIV/AIDS, which was not statistically significant. The models had good calibration and high levels of explained variation and discrimination. In women, the algorithm explained 59.6% of the variation in time to diagnosis of cardiovascular disease (R2, with higher values indicating more variation), and the D statistic was 2.48 and Harrell’s C statistic was 0.88 (both measures of discrimination, with higher values indicating better discrimination). The corresponding values for men were 54.8%, 2.26, and 0.86. Overall performance of the updated QRISK3 algorithms was similar to the QRISK2 algorithms. Conclusion Updated QRISK3 risk prediction models were developed and validated. The inclusion of additional clinical variables in QRISK3 (chronic kidney disease, a measure of systolic blood pressure variability (standard deviation of r...

Treatment use in prognostic model research: a systematic review of cardiovascular prognostic studies

“…Three important developments in the past 4 years include the ACC/AHA Pooled Cohort equations [16], the Globorisk CVD assessment tool [19], and the Qrisk-3 calculator [20], each developed as tools for the prediction of CVD in the general population. Among these three currently implemented CVD risk estimators, there is no clear consensus over how treatments should be taken into account in prognostic models for CVD; treatment use at baseline is modelled differently in each of the prognostic models, and none of the studies accounted for the effects of treatment drop-in.…”

Development and validation of a cardiovascular disease risk-prediction model using population health surveys: the Cardiovascular Disease Population Risk Tool (CVDPoRT)

“…7,8 For individual use, the CVDPoRT's discrimination is exceeded only by QRISK3 -an algorithm that was also developed using "big" data; however, QRISK3 used clinical data that focused on clinical measures (lipids, blood pressure and disease states). 36,37 Clinicians and patients appear to favour health behaviour interventions over medications for patients at low and medium risk, 38 but existing cardiovascular risk algorithms seldom assess the role of health behaviours beyond smoking. 2,39 This means that clinicians have difficulty communicating the degree to which health behaviours contribute to cardiovascular risk, as well as the potential benefit from behavioural interventions.…”

Diabetes outcomes in people with severe mental illness

“…The QRISK3 tool 10 now includes SMI and antipsychotic medication as risk factors influencing overall cardiovascular risk. These variables are also included in the QDIABETES prediction tool.…”

“…These variables are also included in the QDIABETES prediction tool. 10 Taken together, the NDA of SMI, the QRISK3 and QDIABETES tools offer clinicians real opportunities to improve care on an individual basis. A practice-based audit focusing on piloting innovations in interventions to reduce QRISK3 and QDIABETES scores of people with an SMI would be a useful exercise, especially when there is no national guidance on the management of cardiovascular risk in this group other than the rigorous application of general NICE guidelines.…”